Lead scientist Professor Paul Tesar, from Case Western Reserve School of Medicine, said: 'We appreciate that some patients or their families feel they cannot wait for the development of specific approved medications, but off-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms.
[